Home » Topics » BioWorld Science

BioWorld Science
RSS

RBD-PB6 RNA aptamer blocks SARS-CoV-2 entry into host cells

Jan. 14, 2022

Modulation of IL-19 regulates DNA damage-induced cytokine production

Jan. 13, 2022

Hemogenyx and Selexis agree to develop cell line for Hemogenyx's CDX bispecific antibody

Jan. 13, 2022

Immix reports promising response rate with IMX-110 in first-line therapy-resistant STS mouse study

Jan. 13, 2022

Lantern Pharma expands collaboration with NCI to support progression of LP-184 and LP-284

Jan. 13, 2022

Researchers restore front-line antibiotics' effects

Jan. 13, 2022

Alchemedicine discovers CK1 and/or TGFBR1 inhibitors

Jan. 13, 2022

Roche synthesizes new Mat2A inhibitors

Jan. 13, 2022

AstraZeneca identifies new PARP-1 inhibitors

Jan. 13, 2022

Merck Sharp & Dohme presents new SCN10A blockers

Jan. 13, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...